Kristy Pope
Primary Care · Lillington, NCNPI 1912548595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,215 and has fallen 82.2% since, to $216 in 2025. Among primary care clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$817
- Merck$374
- Lilly USA, LLC$296
- Viiv Healthcare Company$228
- Mylan Specialty L.p.$223
- Johnson & Johnson$200
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,83399%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $817 |
| Merck | 22 | $374 |
| Lilly USA, LLC | 17 | $296 |
| Viiv Healthcare Company | 10 | $228 |
| Mylan Specialty L.p. | 10 | $223 |
| Johnson & Johnson(2 entities) | 11 | $200 |
| AbbVie | 10 | $172 |
| Boehringer Ingelheim | 8 | $145 |
| Theratechnologies Inc. | 5 | $138 |
| Paratek Pharmaceuticals, Inc. | 8 | $138 |
| Exact Sciences | 6 | $120 |
| GSK | 5 | $104 |
| Gilead | 4 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Pfizer | 4 | $69 |
| AstraZeneca | 4 | $62 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Corcept Therapeutics | 3 | $59 |
| Bayer | 2 | $51 |
| Amarin Pharma, Inc. | 2 | $37 |
| Novartis | 2 | $35 |
| Shionogi Inc | 2 | $33 |
| Amgen | 2 | $31 |
| Shield Therapeutics Inc | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Eisai Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Medtronic | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$125
How this compares
$3,878 in reported general payments places this provider in the 90th percentile of 236 primary care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $71,584 |
| OzempicSemaglutide | 69 | $64,953 |
| FarxigaDapagliflozin Propanediol | 33 | $35,867 |
| TrulicityDulaglutide | 29 | $34,634 |
| XareltoRivaroxaban | 28 | $28,753 |
| JardianceEmpagliflozin | 19 | $20,446 |
| JanuviaSitagliptin Phosphate | 18 | $19,295 |
| MounjaroTirzepatide | 16 | $16,718 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,726 |
| MyrbetriqMirabegron | 15 | $8,338 |
| SynthroidLevothyroxine Sodium | 36 | $3,396 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,137 |
| Atorvastatin Calcium | 336 | $2,477 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,383 |
| Omeprazole | 163 | $2,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $71,58469 claims |
| Novo NordiskOzempic | $817 | $64,95369 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $296 | $51,35245 claims |
| AstraZenecaFarxiga | $62 | $35,86733 claims |
| Johnson & JohnsonXarelto | $200 | $28,75328 claims |
| Boehringer IngelheimJardiance | $145 | $20,44619 claims |
| MerckJanuvia | $374 | $19,29518 claims |
| GSKAnoro Ellipta | $104 | $10,72623 claims |
| AbbVieSynthroid | $172 | $3,39636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 236 primary care providers in North Carolina.
Other primary care in Lillington
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
- Mark HollingsworthWilmington$7K
- Crystal GoinsFayetteville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.